Recruiting for COVID clinical trial

NORS2791 product candidate will be a topical formulation of NORSTM for the treatment of acne, a chronic, inflammatory skin condition. This formulation will be delivered as a topical gel.

Acne is the most common skin condition seen by physicians. It occurs when pores become clogged by a combination of sebum, an oily substance produced by the skin, dirt and dead skin cells.

Often, bacteria called Propionibacterium acnes is present, which can contribute to the redness, swelling and pus accompanying lesions.

Over 90% of individuals in the global population are affected by acne at some point in their life. Approximately 20% of the US population is affected by acne each year, with an estimated $5 billion market.

NORSTM acts as an antibacterial, but may also inhibit production of pore-clogging cytokines. Specifically, NORSTM has been shown to be highly effective at killing P. acnes. In addition to its bactericidal effect, SaNOtize’s acne treatment is expected to reduce inflammation and thus, acne symptoms.

logged in